Kurs
-0,38%
Likviditet
1 728 MSEK
Kalender
| Est. tid* | ||
| 2025-04-29 | - | Kvartalsrapport 2025-Q1 |
| 2025-04-11 | - | Årsstämma |
| 2025-02-20 | - | X-dag halvårsutdelning AZN 167.999995 |
| 2025-02-06 | - | Bokslutskommuniké 2024 |
| 2024-11-12 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-08 | - | X-dag halvårsutdelning AZN 77.600002 |
| 2024-07-25 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-25 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-11 | - | Årsstämma |
| 2024-02-22 | - | X-dag halvårsutdelning AZN 155.999994 |
| 2024-02-08 | - | Bokslutskommuniké 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-10 | - | X-dag halvårsutdelning AZN 71.799999 |
| 2023-07-28 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-27 | - | Årsstämma |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | - | X-dag halvårsutdelning AZN 162.800002 |
| 2023-02-09 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-11 | - | X-dag halvårsutdelning AZN 76.4 |
| 2022-07-29 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-29 | - | Årsstämma |
| 2022-04-29 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | X-dag halvårsutdelning AZN 145.299995 |
| 2022-02-10 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-12 | - | X-dag halvårsutdelning AZN 64.8 |
| 2021-07-29 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-11 | - | Årsstämma |
| 2021-04-30 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | X-dag halvårsutdelning AZN 137.399995 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-13 | - | X-dag halvårsutdelning AZN 69.599998 |
| 2020-07-30 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-29 | - | Årsstämma |
| 2020-04-29 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | X-dag halvårsutdelning AZN 146.399999 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-10-24 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-08 | - | X-dag halvårsutdelning AZN 71.899998 |
| 2019-07-25 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-26 | - | Årsstämma |
| 2019-04-26 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-28 | - | X-dag halvårsutdelning AZN 146.800005 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-08 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-09 | - | X-dag halvårsutdelning AZN 68.400002 |
| 2018-07-26 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-18 | - | Årsstämma |
| 2018-05-18 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | X-dag halvårsutdelning AZN 133.599997 |
| 2018-02-02 | - | Bokslutskommuniké 2017 |
| 2017-11-09 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-10 | - | X-dag halvårsutdelning AZN 68.900001 |
| 2017-07-27 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-27 | - | Årsstämma |
| 2017-04-27 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | - | X-dag halvårsutdelning AZN 150.199997 |
| 2017-02-02 | - | Bokslutskommuniké 2016 |
| 2016-11-10 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-11 | - | X-dag halvårsutdelning AZN 68.699998 |
| 2016-07-28 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-29 | - | Årsstämma |
| 2016-04-29 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | - | X-dag halvårsutdelning AZN 145.555556 |
| 2016-02-04 | - | Bokslutskommuniké 2015 |
| 2015-11-05 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-13 | - | X-dag halvårsutdelning AZN 63.88889 |
| 2015-07-30 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-24 | - | Årsstämma |
| 2015-04-24 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-19 | - | X-dag halvårsutdelning AZN 138.888896 |
| 2015-02-05 | - | Bokslutskommuniké 2014 |
| 2014-11-06 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-13 | - | X-dag halvårsutdelning AZN 59 |
| 2014-07-31 | - | Kvartalsrapport 2014-Q2 |
| 2014-04-24 | - | Årsstämma |
| 2014-04-24 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-19 | - | X-dag halvårsutdelning AZN 129.777777 |
| 2014-02-06 | - | Bokslutskommuniké 2013 |
| 2013-10-31 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-14 | - | X-dag halvårsutdelning AZN 65.777779 |
| 2013-08-01 | - | Analytiker möte 2013 |
| 2013-08-01 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-25 | - | Årsstämma |
| 2013-04-25 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-13 | - | X-dag halvårsutdelning AZN 133.888888 |
| 2013-01-31 | - | Bokslutskommuniké 2012 |
| 2012-10-25 | - | Analytiker möte 2012 |
| 2012-10-25 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-08 | - | X-dag halvårsutdelning AZN 64.555556 |
| 2012-07-26 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-26 | - | Årsstämma |
| 2012-04-26 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-15 | - | X-dag halvårsutdelning AZN 137.333333 |
| 2012-02-02 | - | Bokslutskommuniké 2011 |
| 2011-10-27 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-03 | - | X-dag halvårsutdelning AZN 57.666665 |
| 2011-07-28 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-28 | - | Årsstämma |
| 2011-04-28 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-02 | - | X-dag halvårsutdelning AZN 129.666662 |
| 2011-01-27 | - | Bokslutskommuniké 2010 |
| 2010-10-28 | - | Kvartalsrapport 2010-Q3 |
| 2010-08-04 | - | X-dag halvårsutdelning AZN 49.888888 |
| 2010-07-29 | - | Kvartalsrapport 2010-Q2 |
| 2010-04-29 | - | Kvartalsrapport 2010-Q1 |
| 2010-02-03 | - | X-dag halvårsutdelning AZN 117.111111 |
| 2010-01-28 | - | Bokslutskommuniké 2009 |
| 2009-10-29 | - | Kvartalsrapport 2009-Q3 |
| 2009-08-05 | - | X-dag halvårsutdelning AZN 40 |
| 2009-07-30 | - | Kvartalsrapport 2009-Q2 |
| 2009-04-30 | - | Årsstämma |
| 2009-04-30 | - | Kvartalsrapport 2009-Q1 |
| 2009-02-04 | - | X-dag halvårsutdelning AZN 116.444444 |
| 2008-08-06 | - | X-dag halvårsutdelning AZN 30.888888 |
| 2008-02-06 | - | X-dag halvårsutdelning AZN 75.2222222 |
| 2007-08-08 | - | X-dag halvårsutdelning AZN 28.111111 |
| 2007-02-07 | - | X-dag halvårsutdelning AZN 70 |
| 2006-08-09 | - | X-dag halvårsutdelning AZN 32.562658 |
Beskrivning
| Land | Storbritannien |
|---|---|
| Lista | FTSE 100 |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
AstraZeneca has entered into settlement agreements in the product liability litigations related to Nexium and Prilosec. The agreements effectively resolve the product liability claims that are currently pending in the Multidistrict Litigation in the US District Court for the District of New Jersey, as well as in the Delaware Superior Court and the New Jersey Superior Court. The specific terms of the agreements are confidential.
AstraZeneca continues to believe these claims are without merit and admits no wrongdoing in the settlement agreement. These settlements avoid continued costly litigation and allow the Company to move forward with its purpose of delivering life changing medicines to millions of patients around the world.
A single case remains pending in the US District Court for the Middle District of Louisiana. Trial is scheduled in that case for April 15, 2024.
Financial considerations
AstraZeneca will make payment of $425 million, for which a provision has been taken.
Notes
Nexium and Prilosec
Nexium and Prilosec are prescription only drugs used to treat patients with acid-related symptoms and diseases. Nexium and Prilosec can provide relief for a range of patients, including those who are frustrated by the disruption that the condition causes to their life. Nexium and Prilosec work by binding to and inhibiting the acid pumps of a particular type of cells in the lining the stomach wall to stop the production of stomach acid. In doing so, it lowers the level of acidity in the stomach and helps to heal erosions in the esophagus or ulcers in the stomach and duodenum. Both Nexium and Prilosec are available via prescription to treat these diagnosable conditions and over-the-counter in lower dosages to treat heartburn.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on social media @AstraZeneca (https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)
Contacts
For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).